Educational Course on GvHD

The Goal

The goal of the interactive GvHD educational coure is to deliver a comprehensive overview of the latest advancements in GvHD treatment using ECP therapy, and to foster engaging peer-to-peer discussion that enhances clinical understanding and collaboration.

Agenda

Download Agenda PDF

Day 1 - 4 March 2026

Arrival of participants

19:45 – 20:00
Meeting at hotel lobby

20:00
Dinner with the faculty

Day 2 - 5 March 2026

09:00 – 09:15
Welcome & introduction - Therakos Healthcare Stakeholder Engagement Department

09:15 – 09:30
Medical Device Regulation (MDR) for THERAKOS™ CELLEX™ Photopheresis System in 2026 - Fasi Payman, Medical Affairs, Therakos

09:30 – 10:00
Achieving immune tolerance in GvHD - Prof Thomas Wekerle

10:00 – 10:20
Mechanistic insights into ECP – The role of Immunomodulation - Fasi Payman, Medical Affairs, Therakos

10:20 – 10:30
Interactive discussion

10:30 – 10:45
Coffee break

10:45 – 11:45
Acute GvHD: The role of ECP - Prof Dr Hildegard Greinix
• Patient selection for ECP treatment
• Treatment schedule
• Response assessment
• Steroid/immunosuppressant tapering

11:45 – 12:00
Interactive discussion

12:00 – 13:00
Lunch

13:00 – 13:45
The current and potential use of Extracorporeal Photopheresis in cGvHD - Prof Daniel Wolff
• Pathophysiology
• Biomarkers
• Treatment

13:45 – 14:30
NIH diagnostic criteria for chronic GvHD - Prof Dr Hildegard Greinix
• NIH Consensus on diagnostic and scoring
• Patient selection for ECP therapy based on organ involvement - The Vienna Experience
• Response assessment including change of co-medication especially steroid/immunosuppressant taper

14:30 – 14:45
Interactive discussion

14:45 – 15:00
Coffee break

15:00 – 15:40
Procedural aspects of ECP in GvHD – The Vienna experience - Prof Nina Worel

15:45 – 16:15
Patient cases presented by the HCP attendees – Interactive discussion

16:15 – 16:30
Final remarks and close

Please see the THERAKOS™ CELLEX™ Photopheresis System operator’s Manual for indications, contraindications, warnings, precautions, adverse reactions, and other important information.

GvHD: Graft versus Host Disease, ECP: Extracorporeal Photopheresis, CTCL: Cutaneous T-cell lymphoma, HTx: Heart Transplantation, LuTx: Lung Transplantation, NIH: National Institutes of Health, HCP: Healthcare practitioner

For this course, participants are required to submit one patient case for discussion 15 days in advance of the session

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd
This information is intended for healthcare professionals based in Europe and the Middle East.

Hosted by

Prof Dr Hildegard Greinix

Past President, Worldwide Network for Blood & Marrow Transplantation (WBMT), Medical University of Vienna

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd.

Explore related courses

Oct 21 - 22, 2026

Educational Course on the Management of GvHD

Wellcome Collection, London, United Kingdom

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.